POC 1. Pilot trial in IBD: mean number of recruited patients/month
- Data collected at Beaujon Hospital – Clichy, France
- 12 trials (phase II, III and IV)
- 42 months recruitment period : 21 before vs 21 with CT-SCOUT™
- With CT-SCOUT™, the randomization rate is increased by 3 folds at both ICF signature and randomization
a ≠ b: p=0.01*
c ≠ d: p=0.02*
(*) Wilcoxon signed-rank test
Bouhnik Y et al. European Crohn’s Colitis Organisation (ECCO Congress)
Barcelona, Feb 2017
POC 2. Recruitment in ibd clinical trials depending on CT-SCOUT™ site equipment
Ulcerative Colitis
S/R : 307/149
Randomization increased by 4.0 folds in sites equipped with CT-SCOUT™
Mann-Whitney test
Sites based in Belgium, France, Germany, Spain, UK and Israel
Bouhnik Y et al. UEGW, Oral communication, Barcelona, 22th Oct. 2019
POC 3. Recruitment in ibd clinical trials depending on CT-SCOUT™ site equipment
Crohn’s disease
S/R : 337/140
Randomization increased by 1.9 folds in sites equipped with CT-SCOUT™
Mann-Whitney test
Sites based in Belgium, France, Germany, Spain, UK and Israel
Bouhnik Y et al. UEGW, Oral communication, Barcelona, 22th Oct. 2019
Testimonials
« CT-SCOUTTM represents a true added value to clinical research. It takes only few minutes to operate and study information is updated very quickly »
Hepato-gastroenterology department,
Lyon-Sud University Hospital
Lyon-Sud University Hospital
« CT-SCOUTTM is important for patients because it facilitates their enrolment in clinical trials. Before CT-SCOUT™ we missed out on a lot of patients and now we have dramatically increased accrual in our studies. We communicate on it and this has clearly increased our visibility at national and international levels »
President, GETAID and ECCO